跳至主要内容
临床试验/EUCTR2023-000123-37-IT
EUCTR2023-000123-37-IT招募中1 期

Efficacy of CONservative versus invasive therapy in acute Coronary syndrome with plaque Erosion PhenoType - the CONCEPT-ACS trial - CONCEPT-ACS

FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE0 个研究点目标入组 400 人开始时间: 2023年2月6日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
400

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Age >= 18 years;
  • Admission with acute coronary syndrome (unstable angina, NSTEMI and STEMI);
  • A residual vessel diameter stenosis of less than 70% and Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 after wiring of the culprit vessel (and thrombus aspiration, if needed);
  • A diagnosis of plaque erosion by intracoronary OCT imaging of the culprit vessel, with a residual area stenosis <60% and minimum lumen area >3.5 mm2.
  • Signed written informed consent to study participation.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 160
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 240

排除标准

  • Age <18 years old;
  • Left ventricular ejection fraction (LVEF) < 30%;
  • Hypotension, shock, or need for mechanical circulatory support or intravenous vasopressors;
  • Contraindication or known hypersensitivity to any of the study drugs (i.e., aspirin, ticagrelor, heparin, and/or colchicine);
  • Unstable ventricular arrhythmias;
  • Creatinine clearance < 30 ml/min/1.73 m2 (as calculated by MDRD);
  • Severe vessel tortuosity or calcification of the culprit vessel, such that it is unlikely that the OCT catheter can be delivered.
  • The culprit lesion is a stent thrombosis;
  • Life expectancy < 1 year;
  • Known history of systemic inflammatory conditions and/or current use or plans to begin chronic systemic steroid therapy (oral or intravenous) during the study (topical or inhaled steroids are allowed);
  • History of cancer or lymphoproliferative disease within the last 3 years.
  • Refusal to sign the written informed consent to study participation.

研究者

发起方
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE

相似试验